Hold AMGN at ~$423; defer adding until post-Q3 2026 earnings; maintain $399 hard stop; trim into $440-450 resistance
HOLD with simplified execution. The three analysts converge on HOLD as directionally correct; they diverge on trigger architecture and conviction. The correct synthesis preserves the trader's $399 stop (below 50 SMA, below basing floor secondary defense, ~5.7% from spot = ~5.8% drawdown tolerance), defers the add trigger to post-Q3 earnings (avoiding front-loading capital into binary catalyst per 9/18 lesson), and activates the Neutral's trim trigger at $440-450 on volume (capturing upper Bollinger/9/3 prior high resistance). Three binding constraints preclude adding at $423: (1) elevated ATR ($10.40) + binary catalyst + complex scaled-entry framework collapses toward Hold-equivalent returns (9/18 lesson), (2) MACD crossovers fail 30-40% at momentum turning points — the Aggressive analyst's fresh MACD bullish crossover is precisely the knife-catching configuration the 9/8 Overweight decision caught (9/8 lesson), (3) institutional momentum and short-cover flows extend 5-10% beyond raised PTs before mean-reverting — AMGN sitting 5% off 52-week high with quiet volume is more likely to mean-revert on cautious print than extend on clean beat (9/24 reflection). HOLD preserves: 2.41% dividend carry on full position, 0.43-beta defensive profile, $14B cash anchor with 1.6x FCF dividend coverage, V-recovery off $375.65 with intact basing floor, re-engagement optionality at $400-410 pullback post-Q3 OR $440+ reclaim on volume, and catalyst optionality on Q3 earnings, MariTide Phase 3, and dazodalibep commercial launch.
| Position | Action |
|---|---|
| Position at ~$423 ahead of Q3 2026 binary catalyst | Maintain current weight; do not increase concentration |
| Price reaches $440-450 on expanding volume (>4M shares) | Trim 20-25% of position into resistance (upper Bollinger + 9/3 prior high confluence) |
| Confirmed pullback to $400-410 zone post-Q3 earnings with constructive tape and 50 SMA hold on closing basis | Re-engage/add position |
| Beat-and-raise Q3 with constructive MariTide guidance | Add signal post-print at $400-410 zone |
| In-line Q3 print with cautious Q4 commentary | Wait for $400 zone before adding |
| Miss or guidance cut at Q3 | Exit at $405 if stop not yet triggered |
AMGN presents an asymmetric entry opportunity at current levels with confirmed technical breakout, transformational Q2 earnings validating Horizon integration, defensive positioning in higher-for-longer macro, and MariTide as free optionality atop a fortress balance sheet.
| Indicator | Value | Signal |
|---|---|---|
| close_200_sma | 359.53 | bullish |
| close_50_sma | 405.85 | bullish |
| close_10_ema | 407.84 | bullish |
| rsi | 60.86 | neutral |
| macd | +1.01 | bullish |
| macd_histogram | +3.22 | bullish |
| boll_upper | 451.33 | neutral |
| boll_mid | 403.87 | neutral |
| boll_lower | 356.41 | neutral |
| atr | 10.40 | neutral |
| price | 423.64 | neutral |
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
Then: Re-engage/add position
EV: +12%
The bull case relies on selective data interpretation and one-quarter extrapolation while ignoring structural headwinds: a dead-cat technical bounce, unsustainable consensus EPS, $57B debt burden, MariTide as a high-risk Phase 3 bet rather than free optionality, patent cliffs on Prolia/XGEVA, and the stock sitting near 52-week highs ahead of a binary Q3 earnings catalyst with negative skew.
· concedes: Bull's case is well-presented; Q2 2026 operating leverage is real, even if base is post-Horizon normalization; Some forward PE discount vs peers is valid; Net debt reduction of $5B is genuine progress; 6.3x interest coverage is decent; MariTide Phase 3 readout could be positive
→ vs conservative: Volume argument is wrong: 8.52M shares on an UP day signals short-covering capitulation, not distribution; quiet volume above key moving averages is signature of institutional accumulation, not distribution
→ vs conservative: 52% EPS growth assumption is not disconnected from reality — Q2 2026 operating income up 32% YoY on 9.6% revenue growth proves the deleveraging and synergy ramps are visible in actual results
→ vs conservative: Waiting for $400-410 assumes market will gift that level; stock may never pull back cleanly before launching, and by the time tape confirms constructive action at those levels we could be at $430+
→ vs neutral: Macro interpretation is backwards: Zero Fed cuts already priced means limited further Treasury upside; higher-for-longer with no recession is ideal environment for defensive names with 0.43 beta and 2.41% yield
→ vs neutral: HOLD with $399 stop is asymmetric — willing to give back 6% but not 18% is backwards risk management; $414 stop below today's low is more appropriate for current technical structure
→ vs conservative: Bear case requires both a miss AND management lowering guidance, which Q2 operating leverage makes structurally unlikely; risk-reward is asymmetric to the upside
| open | 414.40 | neutral |
| high | 424.57 | neutral |
| low | 414.37 | neutral |
| volume | 3,438,987 | neutral |
| pre_shock_high | 444.12 | neutral |
| post_shock_low | 375.65 | neutral |
| breakdown_close | 393.17 | bearish |
| key_resistance | 444.12 | neutral |
| key_support | 403.87–405.85 | neutral |
| hard_risk_level | 375.65 | bearish |
Support: 375.65 · 403.87 · 405.85 | Resistance: 444.12 · 451.33
AMGN is rated HOLD with a neutral-to-bullish technical profile. The stock trades at $423.64 (2026-09-29), up 12.8% from the September 15 low of $375.65 but still 4.6% below the pre-shock peak of $444.12. Short-term momentum is bullish with the close above the 10 EMA (407.84) and 50 SMA (405.85), a fresh MACD bullish crossover (+1.01 vs signal -2.22) with expanding histogram (+3.22), and RSI at 60.86 with room to run before overbought territory. The long-term 200 SMA at 359.53 confirms the uptrend remains intact. Key resistance is at 444.12 (breakout trigger) and support clusters at 403.87–405.85 (Bollinger mid-band/50 SMA), with the September 15 low at 375.65 as the hard invalidation level.
Market Cap
$229.0B
PE (TTM)
26.31
Forward PE
17.33
PEG Ratio
2.52
Price/Book
19.59
Beta
0.426
Dividend Yield
2.41%
EPS (TTM)
$16.10
Forward EPS
$24.45
Book Value / Share
$21.62
Revenue (TTM)
$38.1B
Gross Margin (TTM)
71.9%
Operating Margin (TTM)
35.5%
Net Profit Margin (TTM)
22.95%
EBITDA (TTM)
$17.27B
EBITDA Margin
45.3%
Return on Equity (TTM)
91.5%
Return on Assets (TTM)
8.67%
Net Income (TTM)
$8.74B
Cash (Q2'26)
$14.0B
Total Debt
$57.3B
Net Debt
$43.3B
Net Debt/EBITDA
~2.5x
EBITDA/Interest Expense
~6.3x
Stockholders' Equity
$11.7B
Current Ratio (Q2'26)
1.37
Operating Cash Flow (2025)
$9.96B
Free Cash Flow (2025)
$8.10B
CapEx (2025)
$1.86B
Dividends Paid (2025)
$5.12B
FCF/Revenue
~22.7%
FCF/Net Income
~98.9%
Revenue CAGR (2022-2025)
~11.7%
R&D Growth (3 years)
+64%
Dividend Growth (3 years)
+22%
Q2'26 Revenue
$10.05B
Q2'26 YoY Revenue Growth
+9.6%
Q2'26 Operating Income
$3.51B
Q2'26 Net Income
$2.375B
Q2'26 Diluted EPS
$4.37
Q2'26 Free Cash Flow
$3.49B
52-Week High
$447.03
52-Week Low
$274.02
50-Day Avg
$405.73
200-Day Avg
$362.64
Strengths
Concerns
Amgen is a high-quality, defensive mega-cap biotech in the early innings of post-Horizon earnings normalization with strong operating leverage (Q2'26 operating income +32% YoY on revenue +9.6% YoY). The company generates exceptional FCF of $8-10B annually with a clean 99% FCF/NI ratio, while actively deleveraging from $57B total debt toward a more manageable 2.5x Net Debt/EBITDA. Trading near 52-week highs, the stock offers a compelling forward PE of 17.3x versus 26.3x trailing, but much of the positive catalyst may already be priced in, making it best suited for income-oriented, risk-averse investors seeking defensive healthcare exposure with growth optionality.
Macro: Higher-for-longer rates regime: 30-year Treasury at highest since 2002, mortgage rates at 7.58% near 3-year high. Fed priced at 96% probability of zero cuts in 2026 (Polymarket, $8.7M volume). US recession odds at 8% (benign). Sticky inflation confirmed by rising prediction-market probabilities on UK/Japan/Argentina 2026 prints. Equity indices whipsawed on long-end surge but gold bid at $4,147.70/oz indicating rotation, not capitulation. FRED macro series (CPIAUCSL, FEDFUNDS, DGS10, T10Y2Y) unavailable due to offline feed — live values required before sizing.